DRD4

D(4) dopamine receptor · P21917 · DRD4 on Sugi Atlas →

345,609 patent compounds predicted against DRD4, 199,932 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Nemonapride (SCHEMBL50208)	1.00	18/20
Nemonapride (SCHEMBL50209)	1.00	18/20
SCHEMBL62398	0.85	13/20
SCHEMBL62620	0.60	12/20
Mosapride (SCHEMBL16417)	0.54	12/20
SCHEMBL61628	0.78	10/20
SCHEMBL62036	0.69	10/20
Clebopride (SCHEMBL25710)	1.00	8/20
SCHEMBL8078	0.85	8/20
SCHEMBL61347	0.66	8/20
SCHEMBL33323	0.51	8/20
Clozapine (SCHEMBL8397)	1.00	7/20
Rotigotine (SCHEMBL50425)	1.00	7/20
Loxapine (SCHEMBL41625)	0.98	7/20
Loxapine (SCHEMBL41644)	0.78	7/20
Carpipramine (SCHEMBL34949)	0.47	7/20
Piperylone (SCHEMBL25509)	0.42	7/20
Loxapine (SCHEMBL41643)	0.82	6/20
SCHEMBL7929	0.79	6/20
Alizapride (SCHEMBL48937)	0.68	6/20

Clinical trials — most relevant to DRD4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD	PHASE4	UNKNOWN
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)	PHASE4	COMPLETED
Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder	PHASE4	UNKNOWN
A Pharmacokinetic Study of Paliperidone ER	PHASE4	UNKNOWN
A New Pharmacotherapy for Alcohol Dependence: Olanzapine	PHASE3	COMPLETED
New Treatment for Alcohol and Nicotine Dependence	PHASE2/PHASE3	COMPLETED
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM	PHASE3	COMPLETED
Psychopharmacology for Cocaine Dependence - Buspirone	PHASE2	COMPLETED
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement	PHASE2	COMPLETED
Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112	PHASE1	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography	nan	COMPLETED
Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios	nan	COMPLETED
An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD	nan	COMPLETED
Association Between Smoking, Brain Activity, Genes, and ADHD	nan	COMPLETED
A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality	nan	SUSPENDED
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN
Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder	nan	COMPLETED
The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia	nan	COMPLETED
Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder	nan	COMPLETED
Developing Genetic Education for Smoking Cessation	nan	COMPLETED
Emotional Regulation in Children With ND: the Role of Genomic Variation, Proteomic Patterns, and Early Experience	nan	UNKNOWN
The Genetic Basis for Vulnerability to Substance Abuse	nan	COMPLETED
Dopamine and Insulin Resistance	nan	COMPLETED
Attention Deficit Hyperactivity Disorder: Nutrition and Environment	nan	UNKNOWN
Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade	nan	COMPLETED
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis	nan	COMPLETED
Relationship Between Dopamine Genetics, Food Reinforcement, Energy Intake and Obesity	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DRD4 binder may also engage these)

Protein	Name	Similarity
Q60483	—	0.989	Q60483 →
Q6TLJ0	—	0.988	Q6TLJ0 →
ADRB3	Beta-3 adrenergic receptor	0.983	landscape →
Q9XT57	—	0.983	Q9XT57 →
P51436	—	0.983	P51436 →
Q9XT58	—	0.982	Q9XT58 →
O02662	—	0.982	O02662 →
P46626	—	0.980	P46626 →
P34971	—	0.980	P34971 →
P30729	—	0.979	P30729 →
Q95252	—	0.979	Q95252 →
Q9TST4	—	0.979	Q9TST4 →
Q28524	—	0.978	Q28524 →
P79148	—	0.977	P79148 →
HTR6	5-hydroxytryptamine receptor 6	0.976	landscape →
P25962	—	0.976	P25962 →
O88853	—	0.974	O88853 →
P47899	—	0.973	P47899 →
GALR2	Galanin receptor type 2	0.973	landscape →
P26255	—	0.972	P26255 →
KISS1R	KiSS-1 receptor	0.972	landscape →
O88626	—	0.971	O88626 →
ADRA2C	Alpha-2C adrenergic receptor	0.971	landscape →
ADRB1	Beta-1 adrenergic receptor	0.969	landscape →
Q5IS65	—	0.969	Q5IS65 →
Q924U1	—	0.968	Q924U1 →
Q9TST6	—	0.968	Q9TST6 →
Q9TT96	—	0.968	Q9TT96 →
Q9R1C8	—	0.967	Q9R1C8 →
Q96P69	—	0.967	Q96P69 →